Concepedia

Paweł Robak

PR

Statistics

Publications

32

Citations

2.2K

H-Index

20

Active since

2000

Affiliations

Medical University of Lodz(Current)

Copernicus Memorial Hospital

Medical University of Warsaw

Dana-Farber Cancer Institute

Medical University of Lublin

Paweł Robak is an author at Medical University of Lodz specializing in medicine, hematology, and immunotherapy.

ORCID

Top concepts

Publications per year

2000–2024

32

Publications

32

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

, , +6

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 310 citations · Full text

, , +7

Drug resistance in multiple myeloma

Paweł Robak, Izabela Dróźdż, Janusz Szemraj et al. · Cancer Treatment Reviews · 2018 · 270 citations

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu et al. · New England Journal of Medicine · 2024 · 198 citations

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 127 citations

1–5 of 32